Business Wire

ADVA-NETWORK-SECURITY

20.3.2024 14:01:29 CET | Business Wire | Press release

Share
Adva Network Security launches strategic project within European collaboration to create sovereign clouds

Adva Network Security announced today that it is launching a nationally funded project to develop cloud-optimized, secure network access technology. As part of the Important Projects of Common European Interest (IPCEI), a comprehensive funding initiative is underway to create scalable, real-time and open Next-Generation Cloud Infrastructure and Services (IPCEI-CIS) aimed at ensuring digital sovereignty. Among the 19 German companies participating, Adva Network Security is responsible for developing highly secure network access technology featuring an integrated edge cloud and software solution for robust operation. The solution will be an essential component of a European independent cloud platform, enabling the rapid processing of mission-critical and sensitive data at the network edge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320831952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Funded by the European Union – NextGenerationEU (Graphic: Business Wire)

“The security of mission-critical networks poses major challenges for operators: Quantum computing threatens to compromise established security mechanisms, while the push for digitization requires fast and trusted data processing at the edge of networks. Our project within IPCEI-CIS addresses both of these problems and offers very simple operation through automation,” said Wolfgang Keil, senior director of cybersecurity project management at Adva Network Security. “Leveraging our experience in quantum security, protected hosting and the operation of high-security networks, we’re developing highly secure access to the European cloud. This includes protected hosting of virtualized network functions at the edge, enabling sensitive data to be processed safely and quickly on-site before being transferred securely to the cloud.”

The TRUsted cloud connectivity for automated Endpoint SECurity (TRUE-SEC) project was launched on January 1, 2024, and will run for three years. It is funded by the Federal Ministry for Economic Affairs and Climate Protection based on a resolution of the German Bundestag and financed by the European Union. Its mission is to create an innovative solution for secure network access. Renowned for its expertise in the high-security network domain, Adva Network Security has been entrusted with developing this critical component for an end-to-end European cloud infrastructure. In collaboration with many project partners, IPCEI-CIS aims to establish a standardized, open and sustainable cloud infrastructure that ensures future-proof security for data services that are compliant with stringent regulatory requirements. The initiative marks a crucial step in advancing autonomous and sovereign cloud technology across Europe.

“Already deployed across numerous high-security networks, our technology safeguards some of the most sensitive and mission-critical data. Yet, new threat scenarios require continuous improvement. Through our participation in the IPCEI-CIS initiative, we’re making an important contribution to the sovereignty of European cloud infrastructure and services,” commented Michael Roth, GM of Adva Network Security. “The funding will enable us to expand our competence center for network security in Berlin. Our growing team of cybersecurity and network specialists is playing a vital role in driving the security – and thereby the acceptance – of cloud services through innovative and technologically sophisticated solutions. We’re proud to be able to make this contribution and honored to help shape Germany’s digital future.”

About Adva Network Security

Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuard security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320831952/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye